𝔖 Bobbio Scriptorium
✦   LIBER   ✦

131I-metaiodobenzylguanidine treatment in neuroblastoma: Report of two cases

✍ Scribed by Cottino, F. ;Mussa, G. C. ;Madon, E. ;Favero, A. ;Silvestro, L. ;Grazia, G.

Publisher
John Wiley and Sons
Year
1987
Tongue
English
Weight
265 KB
Volume
15
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

✦ Synopsis

Poor results with 131I-meta-iodobenzylguanidine (MIBG) therapy have been obtained in two children with stage IV neuroblastoma treated after partial surgery and unsatisfactory combination chemotherapy. Both patients' response to treatment (four and three 1-month-spaced courses, respectively; cumulative administration of 11.9 and 9.2 GBq) has been characterized by a low isotope concentration in the primary tumor and in the multiple bone metastases and by bone marrow uptake with final severe hematological toxicity. A slight decrease in the primary tumor's volume was observed in one patient at a cumulative dose of 85 Gy; there was no change in the other's at 42 Gy. At an initial, greater isotope concentration delivering 103 Gy, some bone metastases displayed a sharp decrease in uptake that persisted in the successive courses. For both patients a progressive spreading of new tumor localisation in the bones and finally in the soft tissues was observed.

πŸ“œ SIMILAR VOLUMES

Treatment of neuroblastoma with131I-meta
Treatment of neuroblastoma with131I-metaiodobenzylguanidine
✍ Troncone, L. ;Riccardi, R. ;Montemaggi, P. ;Rufini, V. ;Lasorella, A. ;Mastrange πŸ“‚ Article πŸ“… 1987 πŸ› John Wiley and Sons 🌐 English βš– 345 KB

Seven patients with neuroblastoma (six children and one adult) were treated with therapeutic doses of high specific activity 131I-metaiodobenzylguanidine (131I-MIBG). Six patients were in stage IV and unresponsive to conventional treatment. One patient, in stage III, was treated at diagnosis, an app

Position paper: Role of131I-metaiodobenz
Position paper: Role of131I-metaiodobenzylguanidine in the treatment of neuroblastoma
✍ Mastrangelo, Renato; Tornesello, Assunta; Mastrangelo, Stefano πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 67 KB πŸ‘ 1 views

Background. Standard chemo-radiotherapy methods for the treatment of children with advanced neuroblastoma (NBL) including bone marrow transplant approaches have been disappointing. These poor results can be ascribed to the evolution of residual drug-resistant cell populations. Curative attempts shou

Second malignancies in children with neu
Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine
✍ Alberto Garaventa; Claudio Gambini; Giampiero Villavecchia; Andrea Di Cataldo; L πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 127 KB

## Abstract ## BACKGROUND ^131^I‐metaiodobenzylguanidine (^131^I‐MIBG) is selectively taken up by cells of neural crest origin, allowing targeted radiotherapy of tumors such as neuroblastoma (NB) and pheochromocytoma. Radiotherapy may provide additional benefits in the treatment of NB, with modera

Treatment of neuroblastoma with131I-meta
Treatment of neuroblastoma with131I-metaiodobenzylguanidine: Experience of the MΓΌnster/Kassel group
✍ Fischer, M. ;Wehinger, H. ;Kraus, C. ;Ritter, J. ;SchrΓΆter, W. πŸ“‚ Article πŸ“… 1987 πŸ› John Wiley and Sons 🌐 English βš– 205 KB

I-131-metaiodobenzylguanidine was used for treatment of neuroblastoma stage IV in three children after surgery and or chemotherapy had failed to be effective. In two of the children with multilocular lesions, after an impressive improvement of clinical symptoms tumor progression was observed. Becaus

Treatment of neuroblastoma with131I-meta
Treatment of neuroblastoma with131I-metaiodobenzylguanidine: The experience of an Italian study group
✍ Bestagno, M. ;Guerra, P. ;Puricelli, G. P. ;Colombo, L. ;Calculli, G. πŸ“‚ Article πŸ“… 1987 πŸ› John Wiley and Sons 🌐 English βš– 182 KB

Eight patients affected by neuroblastoma were treated with 18 courses of 131I-meta-iodobenzylguanidine (MIBG). They all had been judged as "nonresponders" to conventional treatments. Six had stage IV disease: of these, five, with massive marrow involvement, had poor results, mainly because of marrow